Our cutting-edge proprietary technologies are the driving force behind our strong research and vaccine development pipeline, helping the global health community better prepare for and combat life-threatening infectious disease outbreaks.
OUR INNOVATIVE VACCINE TECHNOLOGY PLATFORMS – ADVAC® AND PER.C6®
Our innovative vaccine technology platforms – AdVac® and PER.C6® – offer real hope for the accelerated development of vaccines and are designed to help the global health community better prepare for and combat life-threatening infectious disease outbreaks.
These are the same technologies that were used in the development and manufacturing of our investigational Ebola vaccine, which is currently deployed in the Democratic Republic of the Congo (DRC) and Rwanda, and were also used to construct our Zika, RSV and HIV vaccine candidates.
The SARS-CoV-2 vaccine research program is leveraging Janssen’s AdVac® and PER.C6® technologies in an effort to help combat the current COVID-19 pandemic.
Janssen’s established vaccine technology has the ability to manufacture millions of doses. Watch this video to learn more.
ADVAC® VIRAL VECTOR TECHNOLOGY
Adenoviruses are a group of viruses that cause the common cold - so they're good for transporting things into humans.
Janssen’s AdVac® vectors are based on a specific type of adenovirus, which has been genetically modified so that it can no longer replicate in humans and cause disease.
|The AdVac® technology works by using an adenovirus as a vector (a carrier) of an antigen’s genetic code, to mimic components of a pathogen (a bacterium, virus, or other disease-causing organism). Antigens are produced to mimic the pathogen, without causing severe disease.|
|When the body encounters the antigen the body will induce both a long-lasting humoral and cellular immune response against the antigen, by producing B cells, antibodies and memory B cells, as well as T helper cells and cytotoxic T cells.|
|In the future, if the body encounters the actual pathogen, the body will be able to respond faster and more effectively to fight the infection, preventing the disease.|
PER.C6® CELL LINE
In order to produce high concentrations of Janssen’s AdVac® vector they are produced in Janssen’s PER.C6® complementing cell line, which supports the production of our replication incompetent adenovirus vectors.
The PER.C6® cell line has special characteristics, which enable them to multiply whilst floating in suspension at high cell densities.
Viral vectors like AdVac® can replicate at high numbers and concentrations in the PER.C6® cell line, providing the ability to rapidly upscale production.
OUR VACCINE TECHNOLOGIES IN ACTION
On March 30, 2020, Johnson & Johnson announced a lead vaccine candidate for COVID-19. The SARS-CoV-2 vaccine research program is leveraging Janssen’s AdVac® and PER.C6® technologies that provide the ability to rapidly develop new vaccine candidates and upscale production of the optimal vaccine candidate.
During the Ebola virus epidemic in West Africa, Janssen responded by accelerating Ebola virus vaccine development and scale up, resulting in the manufacturing of more than two million monovalent vaccine regimens in less than one year – utilizing PER.C6®.